Looking for our Business Solutions? Click here:CloudQuote APIsContact Us
Home
Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

Why ConocoPhillips Stock Zoomed Higher on Thursdayfool.com
Via The Motley Fool · May 8, 2025
Why GoodRx Holdings Stock Triumphed on Thursdayfool.com
Via The Motley Fool · May 8, 2025
Rumble (NASDAQ:RUM) Reports Strong Q1
Video sharing platform Rumble (NASDAQGM:RUM) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 33.7% year on year to $23.71 million. Its GAAP loss of $0.01 per share was 90% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Ziff Davis (NASDAQ:ZD) Beats Q1 Sales Targets
Digital media company Ziff Davis (NASDAQ:ZD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.5% year on year to $328.6 million. The company’s full-year revenue guidance of $1.47 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.14 per share was 8.5% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Why Fluence Energy Stock Crushed the Market Todayfool.com
Via The Motley Fool · May 8, 2025
Astrana Health (NASDAQ:ASTH) Misses Q1 Revenue Estimates
Healthcare services company Astrana Health missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 53.4% year on year to $620.4 million. Next quarter’s revenue guidance of $635 million underwhelmed, coming in 2.7% below analysts’ estimates. Its GAAP profit of $0.14 per share was 33.1% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Golden Entertainment (NASDAQ:GDEN) Misses Q1 Sales Targets
Casino, tavern, and slot machine operator Golden Entertainment (NASDAQ:GDEN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 7.6% year on year to $160.8 million. Its GAAP profit of $0.09 per share was 27.5% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Yelp’s (NYSE:YELP) Q1 Sales Beat Estimates
Local business platform Yelp (NYSE:YELP) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $358.5 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its GAAP profit of $0.36 per share was 10.7% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Paramount’s (NASDAQ:PARA) Q1 Sales Beat Estimates
Multinational media and entertainment corporation Paramount (NASDAQ:PARA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 6.4% year on year to $7.19 billion. Its non-GAAP profit of $0.29 per share was 12% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
nLIGHT (NASDAQ:LASR) Surprises With Strong Q1, Stock Jumps 16.3%
Laser company nLIGHT (NASDAQ:LASR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $51.67 million. On top of that, next quarter’s revenue guidance ($56 million at the midpoint) was surprisingly good and 11.7% above what analysts were expecting. Its non-GAAP loss of $0.04 per share was 78.7% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
These 18 Industries Could Reshape The Global Economy By 2040talkmarkets.com
As the world evolves, new industries are emerging as the key drivers of future economic growth.
Via Talk Markets · May 8, 2025
Clarus (NASDAQ:CLAR) Surprises With Q1 Sales
Outdoor lifestyle and equipment company Clarus (NASDAQ:CLAR) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 12.8% year on year to $60.43 million. Its non-GAAP loss of $0.02 per share was $0.03 below analysts’ consensus estimates.
Via StockStory · May 8, 2025
BeautyHealth (NASDAQ:SKIN) Reports Bullish Q1
Skincare company BeautyHealth (NASDAQ:SKIN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 14.5% year on year to $69.6 million. On the other hand, next quarter’s revenue guidance of $73.5 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP loss of $0.08 per share was 37.6% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
1-800-FLOWERS (NASDAQ:FLWS) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops
E-commerce florist and gift retailer 1-800-FLOWERS (NASDAQ:FLWS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 12.6% year on year to $331.5 million. Its non-GAAP loss of $0.71 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Why The UK-US Trade Deal Won’t Herald A Wider Tariff Climbdowntalkmarkets.com
For Britain, the UK-US deal secures lower tariffs without compromising forthcoming UK-EU talks. And for the US, it signals to investors that the administration is prepared to be flexible on tariffs.
Via Talk Markets · May 8, 2025
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.50 per share was 21.4% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Skillz (NYSE:SKLZ) Delivers Strong Q1 Numbers
Mobile game developer Skillz (NYSE:SKLZ) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 11.2% year on year to $22.41 million. Its GAAP loss of $0.92 per share was 16.4% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Trex’s (NYSE:TREX) Q1 Sales Top Estimates
Composite decking and railing products manufacturer Trex Company (NYSE:TREX) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 9% year on year to $340 million. Its GAAP profit of $0.56 per share was 4.1% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Which S&P500 stocks are showing activity after the closing bell on Thursday?chartmill.com
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.
Via Chartmill · May 8, 2025
One of the Largest Teacher Pension Funds in the U.S. Sold Nvidia, Tesla, and Apple and Piled Into a Popular Pharmaceutical Stock Up 395% Over the Last 5 Yearsfool.com
Via The Motley Fool · May 8, 2025
Tariff Relief For Sale - Price Tag? Buy Americancontent/com
For a market that’s been begging for daylight at the end of the tariff tunnel, this deal was more than symbolic - it was a breakthrough.
Via Talk Markets · May 8, 2025
Hub Group (NASDAQ:HUBG) Reports Sales Below Analyst Estimates In Q1 Earnings
Logistics solutions provider Hub Group (NASDAQ:HUBG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.4% year on year to $915.2 million. The company’s full-year revenue guidance of $3.8 billion at the midpoint came in 5.6% below analysts’ estimates. Its GAAP profit of $0.44 per share was 3% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates.
Via StockStory · May 8, 2025